Parabilis Medicines, Inc. PBLS
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | -50.71% | -18.24% | |||
| Total Depreciation and Amortization | -4.05% | -7.34% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 292.79% | 14.88% | |||
| Change in Net Operating Assets | 10,039.73% | -964.64% | |||
| Cash from Operations | 88.35% | -44.05% | |||
| Capital Expenditure | -3,750.00% | -398.65% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -236.37% | -- | |||
| Cash from Investing | -238.97% | -105.52% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -2,613.19% | -2,688.57% | |||
| Issuance of Common Stock | 8,912,755.56% | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | 352.28% | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | 79,720.97% | |||
| Cash from Financing | 589,511.85% | 421.48% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 11,390.15% | 656.65% | |||